Fair Value Measurements - Contingent Consideration (Details) - USD ($) $ in Thousands |
1 Months Ended | 3 Months Ended | 9 Months Ended | ||||
---|---|---|---|---|---|---|---|
Sep. 30, 2022 |
Jan. 31, 2022 |
Sep. 30, 2022 |
Sep. 30, 2022 |
Dec. 31, 2021 |
Oct. 06, 2021 |
Feb. 25, 2019 |
|
Fair Value Measurements | |||||||
Contingent consideration under RPAs and CPPAs | $ 75 | $ 75 | $ 75 | $ 8,075 | |||
Bioasis | Royalty Purchase Agreement | |||||||
Fair Value Measurements | |||||||
Changes in estimated fair value of contingent consideration | 0 | ||||||
Contingent consideration under RPAs and CPPAs | 100 | 100 | 100 | $ 100 | |||
Payments of contingent consideration | 0 | 0 | |||||
Affitech | Commercial Payment Purchase Agreement | Regulatory milestones | |||||||
Fair Value Measurements | |||||||
Contingent consideration under RPAs and CPPAs | 0 | $ 0 | $ 0 | $ 8,000 | $ 8,000 | ||
Amount of milestone payment | $ 3,000 | $ 5,000 |
X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
X | ||||||||||
- Definition Changes in estimated fair value of contingent consideration. No definition available.
|
X | ||||||||||
- Definition Decrease in contingent consideration due to milestone payment. No definition available.
|
X | ||||||||||
- Definition Liability recorded for contingent consideration under purchase agreements. May include royalty purchase agreements and commercial payment purchase agreements. No definition available.
|
X | ||||||||||
- Definition Payments of contingent consideration. No definition available.
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|